Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2021-08-26 06:30:00
Oslo, Norway, August 26, 2021 - Vaccibody AS, a clinical-stage biopharmaceutical
company dedicated to the discovery and development of vaccines and novel
immunotherapies, today announced its second quarter 2021 results.
The second quarter 2021 report will be available at
https://www.vaccibody.com/financial-reports-and-presentations/
Contact for Vaccibody:
CEO Michael Engsig
Vaccibody AS
info@vaccibody.com
About Vaccibody
Vaccibody AS, is a clinical-stage biopharmaceutical company, dedicated to the
discovery and development of vaccines and novel immunotherapies for the
treatment cancer and infectious diseases. Vaccibody's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen-specific immune responses
and elicit efficacious clinical responses. Its lead product candidates include
VB10.NEO, a cancer neoantigen vaccine, which is exclusively outlicensed to
Genentech and is in Phase 1b for the treatment of locally advanced and
metastatic tumors and Phase 1/2a for the treatment of melanoma, lung-, head and
neck, renal-, and bladder cancer